Lucia Morandi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucia Morandi has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
M. Mora
Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy
5 shared publications- Marina Mora
Neuromuscular Diseases and Neuroimmunology Unit, Foundation IRCCS Neurological Institute C. Besta, Milano, Italy
4 shared publications - Renato Mantegazza
Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
3 shared publications A. Ruggieri
2 shared publications- Adele D' Amico
Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
2 shared publications - Antonella Pini
Pediatric Neuromuscular Unit, IRCCS Institute of Neurological Sciences of Bologna, 40139 Bologna, Italy
2 shared publications
Latest Publications
- 1 October 2015
- Published by Elsevier in Neuromuscular Disorders
- Vol. 25, S277-S278
Late-onset congenital myopathies: Clinical and molecular features
- 1 October 2015
- Published by Elsevier in Neuromuscular Disorders
- Vol. 25, S277-S278
Late-onset congenital myopathies: Clinical and molecular features
- Open Access
- 31 October 2013
- Published by Elsevier in Neuromuscular Disorders
- Vol. 23 (9) , 839-840
P20.4 Antithetic role of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy
- 31 October 2013
- Published by Elsevier in Neuromuscular Disorders
- Vol. 23 (9) , 839-840
Open AccessP20.4 Antithetic role of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy
- Open Access
- 11 September 2013
- Published by Springer Nature in BMC Medical Genetics
- Vol. 14 (1) , 89
Novel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy
Background: Mutations in the PTRF gene, coding for cavin-1, cause congenital generalized lipodystrophy type 4 (CGL4) associated with myopathy. In CGL4, symptoms are variable comprising, in addition to myopathy, smooth and skeletal muscle hypertrophy, cardiac arrhythmias, and skeletal abnormalities. Secondary features are atlantoaxial instability, acanthosis nigricans, hepatomegaly, umbilical prominence and metabolic abnormalities related to insulin resistance, such as diabetes mellitus, hyperlipidemia and hepatic steatosis. Case presentation: We describe a 3 year-old child of Moroccan origin with mild muscle phenotype, mainly characterized by mounding, muscle pain, hyperCKemia and mild caveolin 3 reduction on muscle biopsy. No CAV3 gene mutation was detected; instead we found a novel mutation, a homozygous single base pair deletion, in the PTRF gene. Only after detection of this mutation a mild generalized loss of subcutaneous fat, at first underestimated, was noticed and the diagnosis of lipodystrophy inferred. Conclusions: The PTRF gene should be investigated in patients with hyperCKemia, mild myopathy associated with spontaneous or percussion-induced muscle contractions like rippling or mounding, and no CAV3 mutation. The analysis should be performed even if cardiac or metabolic alterations are absent, particularly in young patients in whom lipodystrophy may be difficult to ascertain.
- 11 September 2013
- Published by Springer Nature in BMC Medical Genetics
- Vol. 14 (1) , 89
Open AccessNovel PTRF mutation in a child with mild myopathy and very mild congenital lipodystrophy
Background: Mutations in the PTRF gene, coding for cavin-1, cause congenital generalized lipodystrophy type 4 (CGL4) associated with myopathy. In CGL4, symptoms are variable comprising, in addition to myopathy, smooth and skeletal muscle hypertrophy, cardiac arrhythmias, and skeletal abnormalities. Secondary features are atlantoaxial instability, acanthosis nigricans, hepatomegaly, umbilical prominence and metabolic abnormalities related to insulin resistance, such as diabetes mellitus, hyperlipidemia and hepatic steatosis. Case presentation: We describe a 3 year-old child of Moroccan origin with mild muscle phenotype, mainly characterized by mounding, muscle pain, hyperCKemia and mild caveolin 3 reduction on muscle biopsy. No CAV3 gene mutation was detected; instead we found a novel mutation, a homozygous single base pair deletion, in the PTRF gene. Only after detection of this mutation a mild generalized loss of subcutaneous fat, at first underestimated, was noticed and the diagnosis of lipodystrophy inferred. Conclusions: The PTRF gene should be investigated in patients with hyperCKemia, mild myopathy associated with spontaneous or percussion-induced muscle contractions like rippling or mounding, and no CAV3 mutation. The analysis should be performed even if cardiac or metabolic alterations are absent, particularly in young patients in whom lipodystrophy may be difficult to ascertain.
- Open Access
- 12 June 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (1) , 1-3
The empowerment of translational research: lessons from laminopathies
The need for a collaborative approach to complex inherited diseases collectively referred to as laminopathies, encouraged Italian researchers, geneticists, physicians and patients to join in the Italian Network for Laminopathies, in 2009. Here, we highlight the advantages and added value of such a multidisciplinary effort to understand pathogenesis, clinical aspects and try to find a cure for Emery-Dreifuss muscular dystrophy, Mandibuloacral dysplasia, Hutchinson-Gilford Progeria and forms of lamin-linked cardiomyopathy, neuropathy and lipodystrophy.
- 12 June 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (1) , 1-3
Open AccessThe empowerment of translational research: lessons from laminopathies
The need for a collaborative approach to complex inherited diseases collectively referred to as laminopathies, encouraged Italian researchers, geneticists, physicians and patients to join in the Italian Network for Laminopathies, in 2009. Here, we highlight the advantages and added value of such a multidisciplinary effort to understand pathogenesis, clinical aspects and try to find a cure for Emery-Dreifuss muscular dystrophy, Mandibuloacral dysplasia, Hutchinson-Gilford Progeria and forms of lamin-linked cardiomyopathy, neuropathy and lipodystrophy.
- Open Access
- 13 December 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 534
Variable disease severity in Saudi Arabian and Sudanese families with c.3924 + 2 T > C mutation of LAMA2
Congenital muscular dystrophy type 1A is caused by mutations in the LAMA2 gene that encodes the laminin α2 chain, a component of the skeletal muscle extracellular matrix protein laminin-211. The clinical spectrum of the disease is more heterogeneous than previously thought, particularly in terms of motor achievement and disease progression. We investigated clinical findings and performed molecular genetic analysis in 3 families from Saudi Arabia and 1 from Sudan in whom congenital muscular dystrophy 1A was suspected based on homozygosity mapping and laminin α2 chain deficiency. We investigated 9 affected individuals from 1 Sudanese and 3 Saudi families in whom MDC1A was suggested by clinical, neuroimaging and/or pathological findings and by homozygosity mapping at the LAMA2 locus. Morphological and immunohistochemical analysis were performed in 3 patients from the 3 Saudi families. SSCP analysis, DNA sequencing and microsatellite analysis were carried out in the 4 index cases. A previously described mutation in the LAMA2 gene, a homozygous T > C substitution at position +2 of the consensus donor splice site of exon 26, was found in the 4 index patients. Clinical evaluation of 9 patients from the 4 families revealed variable disease severity particularly as regards motor achievement and disease progression. Microsatellite analysis showed an identical mutation-associated haplotype in the 4 index cases indicating a founder effect of the mutation in all 4 families. Our data provide further evidence that the clinical spectrum of MDC1A due to a single mutation is heterogeneous, particularly in terms of motor achievement and disease progression, making it difficult to give a reliable prognosis even in patients with identical LAMA2-associated haplotype. The c.3924 + 2 T > C mutation to date has been found only in patients originating from the Middle East or Sudan; therefore laminin 2 chain deficiency in patients from those regions should initially prompt a search for this mutation.
- 13 December 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 534
Open AccessVariable disease severity in Saudi Arabian and Sudanese families with c.3924 + 2 T > C mutation of LAMA2
Congenital muscular dystrophy type 1A is caused by mutations in the LAMA2 gene that encodes the laminin α2 chain, a component of the skeletal muscle extracellular matrix protein laminin-211. The clinical spectrum of the disease is more heterogeneous than previously thought, particularly in terms of motor achievement and disease progression. We investigated clinical findings and performed molecular genetic analysis in 3 families from Saudi Arabia and 1 from Sudan in whom congenital muscular dystrophy 1A was suspected based on homozygosity mapping and laminin α2 chain deficiency. We investigated 9 affected individuals from 1 Sudanese and 3 Saudi families in whom MDC1A was suggested by clinical, neuroimaging and/or pathological findings and by homozygosity mapping at the LAMA2 locus. Morphological and immunohistochemical analysis were performed in 3 patients from the 3 Saudi families. SSCP analysis, DNA sequencing and microsatellite analysis were carried out in the 4 index cases. A previously described mutation in the LAMA2 gene, a homozygous T > C substitution at position +2 of the consensus donor splice site of exon 26, was found in the 4 index patients. Clinical evaluation of 9 patients from the 4 families revealed variable disease severity particularly as regards motor achievement and disease progression. Microsatellite analysis showed an identical mutation-associated haplotype in the 4 index cases indicating a founder effect of the mutation in all 4 families. Our data provide further evidence that the clinical spectrum of MDC1A due to a single mutation is heterogeneous, particularly in terms of motor achievement and disease progression, making it difficult to give a reliable prognosis even in patients with identical LAMA2-associated haplotype. The c.3924 + 2 T > C mutation to date has been found only in patients originating from the Middle East or Sudan; therefore laminin 2 chain deficiency in patients from those regions should initially prompt a search for this mutation.
- Open Access
- 15 September 2011
- Published by IntechOpen
Idiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis
- 15 September 2011
- Published by IntechOpen
Open AccessIdiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis
- 30 September 2009
- Published by Elsevier in Neuromuscular Disorders
- Vol. 19 (8-9) , 554
EM.P.2.08 Fukutin gene mutations in an Italian patient with early onset muscular dystrophy but no central nervous system involvement
- 30 September 2009
- Published by Elsevier in Neuromuscular Disorders
- Vol. 19 (8-9) , 554
EM.P.2.08 Fukutin gene mutations in an Italian patient with early onset muscular dystrophy but no central nervous system involvement
- 31 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 737
G.P.2.07 Alpha-dystroglycanopathy in an Italian patient due to large intragenic and single nucleotide deletions in the POMGnT1 gene
- 31 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 737
G.P.2.07 Alpha-dystroglycanopathy in an Italian patient due to large intragenic and single nucleotide deletions in the POMGnT1 gene
- 31 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 726-727
D.P.1.02 A robust tool to quantify disability in patients affected by facioscapulohumeral muscular dystrophy
- 31 October 2008
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (9-10) , 726-727
D.P.1.02 A robust tool to quantify disability in patients affected by facioscapulohumeral muscular dystrophy
- 1 November 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (5) , 303-311
High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm
The condition of persistently high plasma CK levels is frequently encountered in asymptomatic patients with normal neurological examination. This condition may be the unique manifestation of several neuromuscular disorders, whose diagnosis is now possible using new diagnostic techniques. However, even if these patients are intensely investigated, specific diagnoses are not always forthcoming. Because of the lack of a widely accepted diagnostic protocol, hyperCKaemia in asymptomatic subjects is a potentially difficult clinical problem. In this paper we review the literature on conditions associated with variations in plasma CK levels and the literature on investigations carried out in asymptomatic persons with high CK to identify neuromuscular diseases. In the light of these data, and the deliberations of a working group of the Italian Association of Myology, we propose a diagnostic algorithm to guide the diagnostic work-up of persons presenting with persistently high levels of plasma CK. This algorithm has been discussed and approved by the Committee of the Italian Association of Myology.
- 1 November 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (5) , 303-311
High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm
The condition of persistently high plasma CK levels is frequently encountered in asymptomatic patients with normal neurological examination. This condition may be the unique manifestation of several neuromuscular disorders, whose diagnosis is now possible using new diagnostic techniques. However, even if these patients are intensely investigated, specific diagnoses are not always forthcoming. Because of the lack of a widely accepted diagnostic protocol, hyperCKaemia in asymptomatic subjects is a potentially difficult clinical problem. In this paper we review the literature on conditions associated with variations in plasma CK levels and the literature on investigations carried out in asymptomatic persons with high CK to identify neuromuscular diseases. In the light of these data, and the deliberations of a working group of the Italian Association of Myology, we propose a diagnostic algorithm to guide the diagnostic work-up of persons presenting with persistently high levels of plasma CK. This algorithm has been discussed and approved by the Committee of the Italian Association of Myology.